OasisLMS

AKI and Hepatorenal Syndrome: Diagnosis, Management, and Treatment

Advances in Inflammation Mechanisms and Therapies to Reduce Atherosclerotic Cardiovascular Disease in Persons with Kidney Diseases

Regulating the Regulator: Exploring the Therapeutic Landscape for Complement-Mediated Kidney Diseases

Emerging Therapies for ANCA-Associated Vasculitis

Basics to Bedside: State-of-the-Art Rationale and Approach to Hyperkalemia in Kidney Diseases

A Practical Approach to Using SGLT2 Inhibitors for Cardiorenal Protection

Breaking Barriers: Advances in Understanding and Treating Complement-Mediated Kidney Diseases

Acute Kidney Dysfunction in Cirrhosis: A Case-Based Conversation about Diagnosis and Treatment

Caring for the Patient with AKI in Cirrhosis: New Tools and Opportunities

Complement in IgA Nephropathy and Lupus Nephritis: Role in Pathogenesis and Implications for Treatment

Current Therapies and Treatment Responses in Primary Focal Segmental Glomerulosclerosis and IgA Nephropathy

Autosomal Dominant Polycystic Kidney Disease: Risk Assessment and Management

Considerations for Incorporating Hemodiafiltration into Dialysis Care

Glucagon-Like Peptide-1 Receptor Agonists and Diabetic Kidney Disease

IgA Nephropathy: Proteinuria, Vasoactive Peptides, and the Evolving Treatment Landscape

Hyperkalemia: Understanding and Applying Innovative Approaches to the Management of CKD and ESKD

Emerging Paradigms in Primary Hyperoxaluria Type 1

Causes and Treatments for CKD-Associated Pruritus

Expanding Therapeutic Horizons in IgAN

Hyperkalemia, CKD, and Heart Failure: Dietary and Medical Considerations

Cytokines and IgA Nephropathy: Pathogenesis and Novel Therapies

Hope in ADPKD: Innovation in Therapeutics

HIF-PHIs Offer Hope for Anemia in CKD

Diagnostic Controversies in Transplantation: Of Biomarkers and Biopsies

Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitors, CVD, and Hyporesponsiveness to Erythropoiesis-Stimulating Agents in ESKD

Expanding Therapeutic Landscape in Lupus Nephritis: Utilization of B Cell Targeted Therapy

Glucagon-Like Peptide-1 Receptor Agonists Are Becoming Important Players in Diabetic Kidney Disease

IgA Nephropathy: The Role of the Renal Endothelin System and Other Therapeutic Implications

Hepatorenal Syndrome Type 1: Advances in Management

Hepatorenal Syndrome Type 1: Diagnosis Methods and Management

Inflammation at the Crossroads: Atherosclerotic Cardiovascular Disease and CKD Interactions

Targeting Cytokines in IgA Nephropathy: Understanding and Taking Aim at the "First-Hit"

Principles of Gout Management in Patients with Kidney Diseases

Hyperphosphatemia Management in Adults Treated with Dialysis for Kidney Failure: Old Lessons, New Directions

Knowing Your Options: Understanding Therapies for Hyperkalemia Management to Aid Decision-Making with Patients Treated with Hemodialysis

HIF-PH Inhibitors: Moving Beyond Erythropoietin and Iron Deficiency

Management of RAAS Inhibitor Therapy After Hyperkalemia in Patients with CKD and Heart Failure

Imaging and Multidisciplinary Care in ADPKD

Radiofrequency Renal Denervation: The Next Frontier for Difficult-to-Control Hypertension

Management of Hyperphosphatemia in Patients with ESKD, Especially During the COVID-19 Pandemic

Mineralocorticoid Receptors: From Bedside to Bench and Back

Moving the Needle: Updated Evidence on Metabolic Acidosis

Optimizing B Cell-Targeted Therapies for Lupus Nephritis: Strategies for Success and Pitfalls to Avoid

Targeting the Pathophysiology of Hyperphosphatemia in ESKD: From Physiology to Clinical Innovation

Anemia in CKD and ESKD: From Epidemiology and Pathophysiology to Current Treatments

Recognizing and Managing the Itch of CKD-Associated Pruritus: Scratching the Surface

More Options and More to Come: Update on the Management of Lupus Nephritis

New Era of Anemia of CKD After the Nobel Prize

Prevention of CKD-Associated Hyperphosphatemia in 2025: What Are the Risks and Benefits?

Mechanisms and Advances in ANCA-Associated Vasculitis

Real-World Management of Hyperkalemia in Cardiorenal Patients

Current and Future Approaches to the Diagnostic Assessment and Management of AKI in Patients with Cirrhosis

New Insights in Iron Deficiency Anemia Among Patients with Non-Dialysis CKD

Novel Insights into the Diagnosis and Management of Atypical Hemolytic Uremic Syndrome

Proteinuria and eGFR as Clinical Trial End Points in FSGS

Accepting the Complement: Understanding the Role of Complement and Its Targeted Therapies in IgA Nephropathy

Hyperkalemia in Diabetes and Heart Failure: Optimizing Management to Mitigate Risk

Update on the Management of Recurrent Hyperkalemia Associated with RAAS Inhibitors in Patients with CKD and ESRD

Partners for Life: Optimizing Collaboration of Community and Transplant Nephrologists

Novel Therapeutic Options in Hyperkalemia

Role of Complement in ANCA-Associated Vasculitis

Ushering Renal Denervation from Trials into the Real World

What's New with SGLT2 Inhibitors in 2023

Updates on Therapeutic Options for Anemia in Kidney Diseases

Update on the Epidemiology, Pathogenesis, and Treatment of CKD-Associated Pruritus

Opportunities and Barriers in Diagnosing CKD of Uncertain Etiology

The Role of Hemodiafiltration in the Management of Dialysis-Dependent Chronic Kidney Failure

SGLT2 Inhibitors: Should We Put Them in the Water of Patients with CKD?

Phosphorus Control in Hemodialysis: What’s the Optimal Strategy?

Treatment of Anemia of CKD: What Is the Role of Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors?

Update on Genetic Architecture and Therapy of Polycystic Kidney Diseases

“Pumping” Iron for CKD

Uremic Toxin Removal with Dialysis: Effects of Middle Molecule Clearance on Clinical Outcomes

Removal of Large Middle Molecular Uremic Toxins: Room for Innovation

Strategies to Control Chronic Hyperkalemia in Patients with CKD and ESRD

Targeting Complement in ANCA-Associated Vasculitis